COVID19

The COVID-19 (Novel coronavirus) pandemic has quickly infected over a million people worldwide. At this time, little is known about how patients with rheumatic diseases, many of whom use medications and drugs that suppress the immune system, are affected by the virus. Here is a study for adults with rheumatic diseases, and parents of children with rheumatic diseases. Click the button to learn more about eligibility and participate in the survey.

read more

Rare Diseases Clinical Research Network

The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease...

read more

Clinical Study: PROMISSE

NOW RECRUITING Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE) The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study...

read more

APS ACTION

The primary mission of APS ACTION is to prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research. Their secondary mission is to refine and advance the...

read more

Recent Posts

Our Mission

Founded in 2005, the APS Foundation of America, Inc. is dedicated to fostering and facilitating joint efforts in the areas of education, public awareness, research, and patient services for Antiphospholipid Syndrome (APS) in an effective and ethical manner.

This site complies with the HONcode standard for trustworthy health information: verify here.

Contact

APS Foundation of America, Inc.
P. O. Box 801
LaCrosse, WI 54602-0801